Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Pharmacy | Monthly Briefing

Back to Journal Articles

September 2012 Briefing - Pharmacy

Last Updated: October 01, 2012.

 

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 

Here are what the editors at HealthDay consider to be the most important developments in Pharmacy for September 2012. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.

Benzodiazepine Use Linked to Increased Risk of Dementia

FRIDAY, Sept. 28 (HealthDay News) -- New use of benzodiazepines correlates with an increase in the risk of dementia, according to a study published online Sept. 27 in BMJ.

Full Text

Stivarga Approved for Advanced Colorectal Cancer

THURSDAY, Sept. 27 (HealthDay News) -- Stivarga (regorafenib) has been approved by the U.S. Food and Drug Administration to treat colorectal cancer that has spread despite prior treatment.

colon and rectal cancer

Denosumab Studied As Therapy for Giant-Cell Tumor of Bone

THURSDAY, Sept. 27 (HealthDay News) -- In patients with giant-cell tumor of bone (GCTB), denosumab treatment causes a significant reduction in tumor giant cells and increased growth of new bone, according to a study published in the Aug. 15 issue of Clinical Cancer Research.

Abstract
Full Text (subscription or payment may be required)

Topical NSAIDs Effective for Chronic Musculoskeletal Pain

THURSDAY, Sept. 27 (HealthDay News) -- Topical nonsteroidal anti-inflammatory drugs (NSAIDs) can provide effective pain relief for chronic musculoskeletal pain in adults, according to a review published online Sept. 12 in The Cochrane Library.

Abstract
Full Text (subscription or payment may be required)

Choice of Psoriasis Treatment Affects CVD Event Rates

THURSDAY, Sept. 27 (HealthDay News) -- Compared with other anti-psoriatic therapies, systemic anti-inflammatory treatment of patients with severe psoriasis with biologic agents or methotrexate is associated with a lower combined risk of death, myocardial infarction, and stroke, according to research published online Sept. 11 in the Journal of Internal Medicine.

Abstract
Full Text (subscription or payment may be required)

Drugs Similar in Efficacy for Neuropathic Pain in Diabetes

WEDNESDAY, Sept. 26 (HealthDay News) -- In the treatment of patients with chronic diabetic peripheral neuropathic pain (DPNP), there are no significant differences in pain-relief efficacy between amitriptyline, duloxetine, and pregabalin; however, pregabalin improves sleep continuity and duloxetine improves daytime functioning, according to research published online Sept. 18 in Diabetes Care.

Abstract
Full Text (subscription or payment may be required)

Efficacy of Black Cohosh for Menopausal Symptoms Unclear

WEDNESDAY, Sept. 26 (HealthDay News) -- There is insufficient evidence to support the use of black cohosh for menopausal symptoms, according to the results of a systematic literature review published online Sept. 12 in The Cochrane Library.

Abstract
Full Text (subscription or payment may be required)

Antibiotic Use Varies by Season, Geographic Region for Elderly

WEDNESDAY, Sept. 26 (HealthDay News) -- Antibiotic usage among older adults varies widely by geographical region and season, according to a study published online Sept. 24 in the Archives of Internal Medicine.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Watch & Wait OK in Low-Tumor Burden Follicular Lymphoma

TUESDAY, Sept. 25 (HealthDay News) -- An initial watch-and-wait strategy does not have a detrimental effect on the freedom from treatment failure (FFTF) or overall survival rate in selected patients with low-tumor burden follicular lymphoma compared with patients initially treated with rituximab-containing regimens, according to research published online Sept. 24 in the Journal of Clinical Oncology.

Abstract
Full Text (subscription or payment may be required)
Editorial

Best Mouse Model of Tumor Drug Exposure Identified

TUESDAY, Sept. 25 (HealthDay News) -- Compared with mouse or human melanomas transplanted into mice, a genetically-engineered mouse melanoma model best approximates the tumor pharmacokinetics of a melanoma drug observed in patients, according to a study published online Sept. 19 in The Oncologist.

Abstract
Full Text (subscription or payment may be required)

Childhood Antibiotic Exposure Linked to Development of IBD

MONDAY, Sept. 24 (HealthDay News) -- Early exposure to antianaerobic antibiotics in childhood is associated with an increased risk of developing inflammatory bowel disease (IBD), according to research published online Sept. 24 in Pediatrics.

Abstract
Full Text (subscription or payment may be required)

Limited Evidence on Medication Use for Youth With Autism

MONDAY, Sept. 24 (HealthDay News) -- There is a lack of evidence supporting the use of medications in adolescents and young adults with autism spectrum disorders (ASDs), according to a review published online Sept. 24 in Pediatrics.

Abstract
Full Text (subscription or payment may be required)

Channel Blockers Reduce Causes of Asthma Symptoms

THURSDAY, Sept. 20 (HealthDay News) -- Epithelial expression of the calcium-activated chloride channel (CaCC) TMEM16A is increased in patients with asthma, and its inhibition negatively regulates epithelial mucin secretion and airway smooth muscle contraction, according to a study published online Sept. 17 in the Proceedings of the National Academy of Sciences.

Abstract
Full Text (subscription or payment may be required)

Drug Improves Social Function in Fragile X Syndrome

THURSDAY, Sept. 20 (HealthDay News) -- A γ-aminobutyric acid type B (GABAB) agonist, STX209 (Arbaclofen), can significantly improve social function in patients with fragile X syndrome, according to a study published in the Sept. 19 issue of Science Translational Medicine.

Abstract
Full Text (subscription or payment may be required)

Duration of Antiplatelet Drugs for Drug-Eluting Stents Studied

THURSDAY, Sept. 20 (HealthDay News) -- In patients receiving drug-eluting stents, dual antiplatelet therapy can be safely discontinued during the first year, according to two studies published online Sept. 19 in the Journal of the American College of Cardiology.

Abstract - Ferreira-González
Full Text
Abstract - Kim
Full Text
Editorial

Linaclotide Relieves Symptoms of IBS With Constipation

THURSDAY, Sept. 20 (HealthDay News) -- Over 26 weeks of treatment, the peptide guanylate cyclase-C agonist linaclotide significantly improves abdominal pain and bowel symptoms in patients with irritable bowel syndrome with constipation (IBS-C), according to research published online Sept. 18 in the American Journal of Gastroenterology.

Abstract
Full Text

Sequential Oral, Topical Tacrolimus Benefits Dermatitis

THURSDAY, Sept. 20 (HealthDay News) -- Sequential therapy with oral tacrolimus and topical tacrolimus may be an effective treatment for severe atopic dermatitis (AD), according to a pilot study published in the October issue of the Journal of the American Academy of Dermatology.

Abstract
Full Text (subscription or payment may be required)

AHA: Sesame, Rice Oil Blend Lowers Blood Pressure

THURSDAY, Sept. 20 (HealthDay News) -- Daily use of a blend of sesame and rice bran oils can significantly lower blood pressure and lipids in patients with hypertension, according to a study presented at the American Heart Association's High Blood Pressure Research Scientific Sessions, held from Sept. 19 to 22 in Washington, D.C.

Press Release
More Information

Oral Dimethyl Fumarate Promising for Multiple Sclerosis

WEDNESDAY, Sept. 19 (HealthDay News) -- For patients with relapsing-remitting multiple sclerosis, treatment with oral BG-12 (dimethyl fumarate) is associated with a reduction in the annualized relapse rate comparable to that found with glatiramer acetate and significantly better than that found with placebo, according to two studies published in the Sept. 20 issue of the New England Journal of Medicine.

Abstract - Fox
Full Text
Abstract - Gold
Full Text
Editorial

Progestogens Not Effective in Multiple Gestations

TUESDAY, Sept. 18 (HealthDay News) -- Progestogen treatment may be beneficial for pregnant women who have previously given birth to preterm babies, but does not seem to be effective for multiple gestations, according to research published online Sept. 5 in Obstetrics & Gynecology.

Abstract
Full Text (subscription or payment may be required)

Resuming Warfarin After GI Bleed Cuts Mortality

TUESDAY, Sept. 18 (HealthDay News) -- In the 90 days following a gastrointestinal tract bleeding (GIB) event, patients who do not resume warfarin therapy experience an increased rate of thrombosis and death, according to research published online Sept. 17 in the Archives of Internal Medicine.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

L-Carnitine Does Not Reduce Cancer-Related Fatigue

TUESDAY, Sept. 18 (HealthDay News) -- Patients with invasive malignancies who take L-carnitine supplements do not experience a reduction in fatigue, pain, or depression, according to research published online Sept. 17 in the Journal of Clinical Oncology.

Abstract
Full Text (subscription or payment may be required)

VTE Risk Varies by Hormone Therapy Formulation

TUESDAY, Sept. 18 (HealthDay News) -- The risk of venous thromboembolism (VTE) in postmenopausal women differs considerably according to the formulation of hormone therapy (HT) used, with the highest VTE risk seen in users of oral estrogen-progestin HT containing medroxyprogesterone acetate, according to research published online Sept. 10 in the Journal of Thrombosis and Haemostasis.

Abstract
Full Text (subscription or payment may be required)

Abiraterone Prolongs Survival in Metastatic Prostate Cancer

TUESDAY, Sept. 18 (HealthDay News) -- Abiraterone acetate significantly improves overall survival in patients with metastatic castration-resistant prostate cancer that has progressed after docetaxel treatment, according to a study published online Sept. 18 in The Lancet Oncology.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Nicotine Replacement Doesn't Increase Cardio Risk After ACS

MONDAY, Sept. 17 (HealthDay News) -- Use of nicotine replacement therapy (NRT) does not increase the risk of adverse cardiovascular events in the first year following acute coronary syndromes (ACS), according to research published in the Oct. 1 issue of The American Journal of Cardiology.

Abstract
Full Text (subscription or payment may be required)

Antipsychotic Use Up Among U.S. Medicaid-Enrolled Youth

FRIDAY, Sept. 14 (HealthDay News) -- There has been a substantial increase in antipsychotic use among Medicaid-enrolled children in recent years, with the increase partially driven by youth with attention-deficit/hyperactivity disorder (ADHD) and those with multiple diagnoses, according to a study published online Sept. 4 in Health Services Research.

Abstract
Full Text (subscription or payment may be required)

Risk of Car Accidents Up With Antidepressant Use

FRIDAY, Sept. 14 (HealthDay News) -- There is an increased risk of motor vehicle accidents (MVAs) for patients taking antidepressants, benzodiazepines, or Z-drugs, according to a study published online Sept. 13 in the British Journal of Clinical Pharmacology.

Abstract
Full Text

Aubagio Approved for Multiple Sclerosis

THURSDAY, Sept. 13 (HealthDay News) -- Aubagio (teriflunomide) has been approved by the U.S. Food and Drug Administration to treat adults with relapsing forms of multiple sclerosis (MS).

multiple sclerosis

Meta-Analysis: Acupuncture Reasonable Chronic Pain Option

THURSDAY, Sept. 13 (HealthDay News) -- Acupuncture is an effective treatment for chronic pain conditions, including back and neck pain, osteoarthritis, and chronic headache, with pain relief superior to both no-acupuncture controls and sham-acupuncture groups, according to the results of a systematic review and meta-analysis published online Sept. 10 in the Archives of Internal Medicine.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Advertising Changes After Drug Switch to Over-the-Counter

THURSDAY, Sept. 13 (HealthDay News) -- When a drug switches from prescription-only to over-the-counter (OTC) there is a shift in the direct-to-consumer advertising (DTCA), with less presentation of potential harms and frequent omission of identification by generic names, according to a research letter published online Sept. 11 in the Journal of the American Medical Association.

Full Text (subscription or payment may be required)

Long-Term Finasteride Doesn't Impair Quality of Life

THURSDAY, Sept. 13 (HealthDay News) -- Taking finasteride to prevent prostate cancer does not negatively affect the physical function, mental health, or vitality domains of health-related quality of life, according to a study published online Sept. 12 in the Journal of the National Cancer Institute.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Tranexamic Acid Safe for Wide Spectrum of Trauma Patients

WEDNESDAY, Sept. 12 (HealthDay News) -- Tranexamic acid reduces risk of death and thrombotic events in patients with traumatic bleeding, irrespective of the baseline risk of death, according to a study published online Sept. 11 in BMJ.

Full Text

Persistence of Statin Use Linked to Decreased Cancer Risk

WEDNESDAY, Sept. 12 (HealthDay News) -- There is an inverse association between statin persistence and cancer risk, particularly for hematopoietic malignancies, according to a study published in the September issue of the U.S. Centers for Disease Control and Prevention's Preventing Chronic Disease.

Full Text

Review: Omega-3s Do Not Reduce Risk of Cardio Events

TUESDAY, Sept. 11 (HealthDay News) -- Supplementation with omega-3 polyunsaturated fatty acids (PUFAs) is not associated with a statistically significant reduction in major cardiovascular end points, according to research published in the Sept. 12 issue of the Journal of the American Medical Association.

Abstract
Full Text (subscription or payment may be required)

No Superior Method of Adjusting Inhaled Steroids in Asthma

TUESDAY, Sept. 11 (HealthDay News) -- For adults with mild-to-moderate asthma controlled with inhaled corticosteroids, adjustment of corticosteroids based on biomarkers (exhaled nitric oxide) or symptoms does not improve the time to treatment failure compared with physician assessment-based adjustment, according to a study published in the Sept. 12 issue of the Journal of the American Medical Association.

Abstract
Full Text
Editorial (subscription or payment may be required)

Less Alzheimer's Pathology With Angiotensin Receptor Blocker Use

TUESDAY, Sept. 11 (HealthDay News) -- In autopsy findings, patients treated with angiotensin receptor blockers (ARBs) show less Alzheimer's disease (AD)-related pathology, according to a study published online Sept. 10 in the Archives of Neurology.

Abstract
Full Text (subscription or payment may be required)

Adding Ketamine to Opioids Doesn't Reduce Cancer Pain

TUESDAY, Sept. 11 (HealthDay News) -- Using subcutaneously administered ketamine in a dose-escalating regimen as an adjunct to opioids and standard co-analgesics does not have any clinical benefit in relieving cancer pain, but it is associated with increased toxicity, according to research published online Sept. 10 in the Journal of Clinical Oncology.

Abstract
Full Text (subscription or payment may be required)

NSAID Use Ups Cardiovascular Risk Up to Five Years Post-MI

MONDAY, Sept. 10 (HealthDay News) -- The increased cardiovascular risk associated with nonsteroidal anti-inflammatory drug (NSAID) use following a first myocardial infarction (MI) persists up to five years, according to a study published online Sept. 10 in Circulation.

Abstract
Full Text (subscription or payment may be required)

Antihypertensive Use in Pregnancy Increasing

MONDAY, Sept. 10 (HealthDay News) -- The prevalence of antihypertensive use in pregnancy is approaching 5 percent and is increasing, according to a study published online Sept. 10 in Hypertension.

Abstract
Full Text (subscription or payment may be required)

Early Prophylactic Tx Beneficial for Hypertrophic Cardiomyopathy

MONDAY, Sept. 10 (HealthDay News) -- Beta blockers (BBs) are effective as an early prophylactic pharmacologic treatment for patients with mild hypertrophic cardiomyopathy (HC) who have exercise-induced left ventricular outflow tract (LVOT) obstruction, according to a study published in the Sept. 1 issue of The American Journal of Cardiology.

Abstract
Full Text (subscription or payment may be required)

Cognitive Deficits for Chemo-Treated Breast Cancer Patients

FRIDAY, Sept. 7 (HealthDay News) -- Breast cancer survivors who were previously treated with chemotherapy experience small cognitive deficits in the domains of verbal ability and visuospatial ability, according to a study published online Aug. 27 in the Journal of Clinical Oncology.

Abstract
Full Text (subscription or payment may be required)
Editorial

Not All Docs/Nurses Want to Be Asked About Hand Hygiene

FRIDAY, Sept. 7 (HealthDay News) -- Although most health care workers (HCWs) appreciate the role of patients in preventing health care-associated infection, a considerable proportion are uncomfortable with patients asking about their hand hygiene, according to a letter published online Sept. 3 in the Archives of Internal Medicine.

Full Text (subscription or payment may be required)

Antiretrovirals Increasingly Used for HIV in the U.S.

FRIDAY, Sept. 7 (HealthDay News) -- Since 2000, more HIV-infected patients in the United States are receiving antiretroviral treatment, viral load has fallen, and CD4 counts at death have risen, according to a study published in the Sept. 4 issue of the Annals of Internal Medicine.

Full Text (subscription or payment may be required)

Bolus Epidural Fentanyl Cuts Post-Spinal Decompression Pain

THURSDAY, Sept. 6 (HealthDay News) -- Intraoperative bolus epidural fentanyl is effective at alleviating early postoperative pain after lumbar canal decompression, according to a study published online Aug. 27 in The Spine Journal.

Abstract
Full Text (subscription or payment may be required)

Ginkgo Biloba Extract Does Not Cut Progression to Alzheimer's

THURSDAY, Sept. 6 (HealthDay News) -- For elderly adults with memory complaints, use of standardized ginkgo biloba extract is no better than placebo for reducing the incidence of Alzheimer's disease, according to a study published online Sept. 6 in The Lancet Neurology.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Bosulif Approved for Chronic Myelogenous Leukemia

WEDNESDAY, Sept. 5 (HealthDay News) -- Bosulif (bosutinib) has been approved by the U.S. Food and Drug Administration to treat chronic myelogenous leukemia (CML), the agency said in a news release.

FDA

Intermittent ADT Noninferior to Continuous ADT for Prostate CA

WEDNESDAY, Sept. 5 (HealthDay News) -- In men with prostate cancer who have rising prostate-specific antigen (PSA) levels after radiotherapy, overall survival is similar if they receive intermittent or continuous androgen-deprivation therapy, according to a study published in the Sept. 6 issue of the New England Journal of Medicine.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Clopidogrel After MI Less Effective in Diabetes Patients

WEDNESDAY, Sept. 5 (HealthDay News) -- Clopidogrel therapy following a heart attack does less to reduce the risk of death in patients with diabetes than in those without diabetes, according to a study published in the Sept. 5 issue of the Journal of the American Medical Association.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Anthracycline, Trastuzumab for Breast CA Up Heart Failure Risk

WEDNESDAY, Sept. 5 (HealthDay News) -- For women with incident, invasive breast cancer, treatment with anthracycline and trastuzumab is associated with an increased risk of heart failure and/or cardiomyopathy, compared to having no chemotherapy, according to a study published in the Sept. 5 issue of the Journal of the National Cancer Institute.

Abstract
Full Text
Editorial

No Increased Risk of Cancer With Biologics in Rheumatoid Arthritis

TUESDAY, Sept. 4 (HealthDay News) -- For patients with rheumatoid arthritis (RA), the use of biologic response modifiers (BRMs) for at least six months is not associated with an increased risk of malignancy compared with placebo or other disease-modifying antirheumatic drugs (DMARDs), according to a study published in the Sept. 5 issue of the Journal of the American Medical Association.

Abstract
Full Text (subscription or payment may be required)

Vitamin D Repletion Offers No Short-Term Benefit in Lipids

TUESDAY, Sept. 4 (HealthDay News) -- For vitamin D deficient adults, repletion of vitamin D is not associated with short-term improvement in the lipid profile, according to a study published online Sept. 4 in Arteriosclerosis, Thrombosis, and Vascular Biology.

Abstract
Full Text (subscription or payment may be required)

Addition of Tiotropium Effective in Poorly Controlled Asthma

TUESDAY, Sept. 4 (HealthDay News) -- For patients with poorly controlled asthma, the addition of tiotropium to standard therapy is beneficial, according to a study published online Sept. 3 in the New England Journal of Medicine to coincide with presentation at the annual meeting of the European Respiratory Society, held from Sept. 1 to 5 in Vienna.

Abstract
Full Text
Editorial
More Information

Copyright © 2012 ScoutNews, LLC. All rights reserved.


Previous: September 2012 Briefing - Pain Management Next: Patients Benefit From Access to Physician Notes

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.